Prostate Specific Antigen (PSA): Results and Screening
Updated
Prostate specific antigen (PSA) is a protein made by the prostate gland, and a blood test for it is the first step in looking for prostate cancer. A raised PSA does not mean cancer, and a low one does not rule it out: benign enlargement, inflammation, a recent biopsy and even ejaculation can push the level up, while some medicines for an enlarged prostate cut it by about half. That is why guidelines no longer treat any single number as safe. This guide explains what PSA is, what raises and lowers it, how results are read with age, PSA density, free PSA and newer blood tests, what the main screening guidelines advise, why MRI now comes before biopsy, and how PSA is used after treatment. Every figure comes from a guideline or study listed in the sources.
- What it isA serine protease from the KLK3 gene, made by prostate epithelial cells
- No safe cut-offIn the PCPT, 15.2% of men who never had a PSA over 4.0 ng/mL had cancer on biopsy
- Lowered byFinasteride and dutasteride, which reduce PSA by about 50% (EAU)
- After surgeryRecurrence is defined as PSA of 0.2 ng/mL or more, confirmed (AUA 2007)
For clinicians and students, the hard part is rarely the number itself but which rule applies to it. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it which benign causes and medicines change a PSA result, and how long the NHS and the EAU advise waiting before a repeat test, and each point links to its source.
Check what can change a PSA result with AskMed:
What is PSA, and what does it do?
PSA is a protein made by both normal and cancerous cells of the prostate, as the National Cancer Institute (NCI) explains, and the blood level rises in benign prostate disease as well as in cancer. Its gene, KLK3 (kallikrein-related peptidase 3), is one of the fifteen kallikrein genes clustered on chromosome 19, according to the NCBI Gene record. Kallikreins are a subgroup of serine proteases, and KLK3 encodes a single-chain glycoprotein that is made in the epithelial cells of the prostate gland and is present in seminal plasma. Its normal job is thought to be liquefying the seminal coagulum, presumably by breaking down the high-molecular-mass protein from the seminal vesicles. In blood, laboratories measure it in nanograms per millilitre (ng/mL). The NCI lists three uses for the blood test: screening men without symptoms, following up urinary or pelvic symptoms, and monitoring men already known to have prostate cancer.
Because PSA reflects prostate tissue rather than cancer itself, the result has to be read with the size of the prostate, recent events, medicines and age in mind. Laboratories can also measure the share of PSA that circulates in free form, which is the basis of the free-to-total ratio and of the Prostate Health Index covered below.
What raises and lowers PSA?
PSA rises with benign prostatic hyperplasia (BPH), prostatitis and infection or inflammation of the prostate, and the NCI notes that a prostate biopsy can raise PSA for a month or two, while vigorous exercise such as cycling and ejaculation can raise it briefly. The NCI advises waiting for temporary conditions to settle and avoiding those activities for 2 days before a test. The NHS gives the same window as 48 hours, covering ejaculation, anal sex, cycling and exercise that leaves a person out of breath, and says to wait 4 to 6 weeks after a urine infection clears before testing. Medicines can push PSA the other way: the EAU guideline states that 5-alpha-reductase inhibitors, finasteride and dutasteride, reduce PSA levels by 50%, so the value should be corrected before deciding on further tests, and the NCI notes that a lower abnormal cut-off is used for men taking them. The EAU also puts the normal variation between two tests in the same man at about 15% either way.
- Raise PSA: BPH, prostatitis, prostate infection or inflammation, a recent biopsy, ejaculation, cycling and vigorous exercise.
- Lower PSA: 5-alpha-reductase inhibitors (finasteride, dutasteride), which roughly halve the value.
- Before a test: avoid ejaculation and strenuous exercise for 48 hours, and wait 4 to 6 weeks after a urine infection (NHS).
This is why the 2023 AUA/SUO guideline asks clinicians to repeat a newly raised PSA before ordering a secondary biomarker, imaging or a biopsy, and why the EAU guideline repeats the test first in men without symptoms whose PSA is 3 to 10 ng/mL.
Is there a normal PSA level?
There is no normal PSA level in the sense of a value below which cancer is absent: the NCI states that there is no single threshold that separates a normal from an abnormal result, only that higher levels make prostate cancer more likely. A level above 4.0 ng/mL has long been treated as abnormal, but the 2023 AUA/SUO guideline explains that the commonly cited 4 ng/mL threshold comes from very early studies and reflects the highest values seen in men thought to be free of cancer. The EAU guideline says there are no agreed standards for an abnormal PSA threshold. In screening trials the most widely used threshold is 3.0 ng/mL or more, which returned a positive test in 16.5% of invited men, and a meta-analysis cited by the EAU found that a threshold of 4.0 ng/mL had a combined sensitivity of 0.93 but a specificity of only 0.20. PSA also rises with age in men without cancer, so some clinicians use age-specific thresholds instead.
Those four values are the ones most studies of age-varying thresholds use, according to the AUA/SUO guideline, which also says clinicians may tailor what counts as an elevated PSA to the clinical situation. The NCI gives a simpler version: some doctors use about 2.5 ng/mL for younger men and about 5 ng/mL for older men. None of these is a reference range to reassure with, as the next section shows.
What did the PCPT show about cancer at low PSA?
The Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer, including high-grade cancer, is not rare in men whose PSA stays at 4.0 ng/mL or less. Thompson and colleagues (N Engl J Med, 2004) studied the placebo group: of 18,882 men enrolled, 9459 received placebo with a yearly PSA and digital rectal examination, and 2950 of them never had a PSA above 4.0 ng/mL or an abnormal examination and still had a biopsy after seven years in the study. These men were aged 62 to 91. Prostate cancer was found in 449 of them (15.2%), and 67 of those cancers (14.9%) had a Gleason score of 7 or higher. The proportion with cancer climbed steadily with PSA, from 6.6% at 0.5 ng/mL or less to 26.9% at 3.1 to 4.0 ng/mL, and the share of cancers that were high grade rose from 12.5% to 25.0% across the same range.
The PCPT result cuts both ways. It means a "normal" PSA cannot exclude cancer, which the EAU guideline echoes when it says some men may harbour prostate cancer despite a low PSA. It also means that lowering the threshold would find many more cancers, most of them low grade, which feeds the overdiagnosis problem behind the screening debate. The trial also gave its name to the PCPT risk calculator, which the AUA/SUO guideline lists among the validated calculators that clinicians and patients may use to inform the biopsy decision.
How do PSA density, velocity, free PSA, PHI and the 4Kscore refine a result?
PSA density, PSA velocity, the free-to-total PSA ratio, the Prostate Health Index (PHI) and the 4Kscore are ways to make a PSA result more specific, so that fewer men with benign disease or low-grade cancer go on to biopsy. PSA density divides the PSA by the prostate volume; the EAU guideline cites a cut-off of 0.15 ng/mL/cc, and men with a density below 0.09 ng/mL/cc were unlikely (4%) to be diagnosed with clinically significant cancer. PSA velocity, the rate of rise over time, adds little: the 2023 AUA/SUO guideline makes it a strong recommendation that velocity should not be the sole reason for a biomarker, imaging or biopsy, because large studies found it added no value once age, PSA, examination and free PSA were known. The free-to-total ratio, PHI and the 4Kscore are blood tests that each have trial data behind them, described below.
- Free-to-total PSA: in a trial of 773 men aged 50 to 75 with PSA 4.0 to 10.0 ng/mL and a benign-feeling prostate, a cut-off of 25% free PSA or less detected 95% of cancers while avoiding 20% of unnecessary biopsies (Catalona, JAMA 1998). A lower percentage meant a higher risk of cancer.
- Prostate Health Index: combines [-2]proPSA, free PSA and total PSA. In 892 men with PSA 2 to 10 ng/mL and a normal rectal examination, its area under the curve for Gleason 4 + 3 or higher disease was 0.724, against 0.670 for the free-to-total ratio (Catalona, J Urol 2011).
- 4Kscore: combines four kallikreins in blood with clinical information. In 1012 men scheduled for biopsy at 26 US centres, Gleason 7 or higher cancer was found in 23%; the area under the curve was 0.82, and 30% to 58% fewer biopsies were possible, with 1.3% to 4.7% of Gleason 7 or higher cancers diagnosed later (Parekh, Eur Urol 2015).
The EAU guideline notes that PHI and the 4Kscore both outperformed the free-to-total ratio for men with PSA between 2 and 10 ng/mL and performed equally in a head-to-head comparison, and it recommends no single test. The NCI adds a caveat that matters in counselling: none of these tests has yet been shown to reduce deaths from prostate cancer. Because each test was validated in a different PSA range and population, the details decide whether a result applies. Ask AskMed which PSA range the 25% free PSA cut-off was validated in, or how PHI and the 4Kscore compared head to head, and the answer cites the trial or guideline section behind each figure.
Look up a secondary PSA biomarker in AskMed:
Who should have PSA screening?
PSA screening is a shared decision rather than a routine test in every major guideline, but the guidelines differ on ages, intervals and risk groups. The US Preventive Services Task Force (USPSTF) 2018 recommendation, still the final statement while an update is under way, gives a grade C for men aged 55 to 69: screening is an individual decision after a discussion of benefits and harms, and clinicians should not screen men who do not express a preference for it. For men aged 70 and older it gives a grade D, recommending against screening. The USPSTF estimates that screening 1000 men aged 55 to 69 for about 13 years prevents about 1.3 prostate cancer deaths and about 3 cases of metastatic cancer, with a number needed to screen of 781. Against that, it estimates that 20% to 50% of screen-detected cancers are overdiagnosed, and that about 1 in 5 men develop long-term urinary incontinence and 2 in 3 long-term erectile dysfunction after radical prostatectomy.
- AUA/SUO (2023, amended 2026): use PSA as the first screening test; clinicians may offer a baseline PSA at 45 to 50; offer screening from 40 to 45 to people at increased risk because of Black ancestry, germline mutations or a strong family history; offer regular screening every 2 to 4 years from 50 to 69. The 2026 amendment revised the statement on personalising re-screening intervals and added material on MRI before a first biopsy and on 5-alpha-reductase inhibitors.
- EAU (2026): offer early PSA testing to well-informed men from 50, from 45 with a family history of prostate cancer before 60 or of African descent, and from 40 with a BRCA2 mutation; repeat every 2 years in men at risk (PSA over 1 ng/mL at 40 or over 2 ng/mL at 60) and postpone for up to 8 years in men who are not; stop according to life expectancy and performance status.
- UK: the UK National Screening Committee does not recommend population screening; in 2026 it recommended a targeted programme of PSA testing every 2 years for men aged 45 to 61 with a disease-causing BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer. The NHS does not offer routine PSA tests otherwise, but men can ask a GP for one after discussing benefits and risks.
The USPSTF made no separate recommendation for Black men or for men with a family history, citing too little evidence, but it notes that incidence is 203.5 per 100,000 in African American men against 121.9 in white men, and that clinicians should tell Black men about their higher risk. These differences matter when one patient's age, ancestry or genetic result places them inside one guideline and outside another. Ask AskMed how the AUA/SUO, EAU and UK NSC positions differ for a 45-year-old man with a BRCA2 variant, and each point is linked to the statement it comes from.
Compare PSA screening guidelines with AskMed:
What happens after a raised PSA? Repeat tests and MRI before biopsy
After a raised PSA, the first step in current guidelines is to repeat the test, and the second is usually an MRI of the prostate rather than a biopsy straight away. The NCI suggests repeating the PSA in 6 to 8 weeks; the EAU guideline repeats it after four weeks for men with a PSA of 3 to 10 ng/mL and no suspicious finding on examination. If the PSA stays raised and lies between 3 and 20 ng/mL, the EAU recommends prostate MRI (a strong recommendation), a calibrated risk calculator or an extra blood or urine biomarker to decide on biopsy. The evidence comes largely from PRECISION (N Engl J Med, 2018), which randomly assigned 500 men who had never had a biopsy. In the MRI arm, 28% had a non-suspicious scan and avoided biopsy, clinically significant cancer was found in 38% against 26% with standard biopsy, and clinically insignificant cancer was diagnosed 13 percentage points less often.
- Raised PSA: check for causes such as infection, a recent biopsy, ejaculation or a 5-alpha-reductase inhibitor.
- Repeat the PSA: after 4 weeks (EAU) or 6 to 8 weeks (NCI), before any biomarker, imaging or biopsy (AUA/SUO).
- Still raised: MRI of the prostate, a risk calculator or a further biomarker, with PSA density where the prostate volume is known.
- Suspicious MRI or high risk: targeted biopsy, transrectal or transperineal; a low-risk result may allow biopsy to be deferred with continued monitoring.
MRI matters because biopsy carries real harms. The NCI notes that only about 25% of men biopsied for a raised PSA are found to have cancer, and that biopsy can cause infection, pain and bleeding; the USPSTF puts hospital admission at about 1% of biopsies. A fever, shivering or difficulty passing urine after a biopsy should be reported to the team that did it straight away. The 2023 AUA/SUO guideline also says that when risk is low enough, clinicians and patients may forgo a near-term biopsy. For how MRI compares with CT more generally, see MRI scan vs CT scan. Anyone with urinary symptoms, blood in the urine or new erection problems should see a doctor, who may suggest a PSA test, as the NHS advises.
How is PSA used after prostate cancer treatment?
After treatment for prostate cancer, PSA becomes the main follow-up test, and a rising level, called biochemical recurrence, is often the first sign that cancer has come back, months or years before any symptoms, according to the NCI. After radical prostatectomy the EAU guideline expects PSA to be undetectable within two months. The AUA panel led by Cookson (J Urol, 2007) found 53 different definitions of recurrence after prostatectomy in 145 articles and recommended a standard: a PSA of 0.2 ng/mL or more, confirmed by a second value above 0.2 ng/mL. After radiotherapy, with or without hormone therapy, the RTOG-ASTRO Phoenix consensus (Int J Radiat Oncol Biol Phys, 2006) defines biochemical failure as a rise of 2 ng/mL or more above the lowest post-treatment value, the nadir, dated when it is found rather than backdated. The EAU advises PSA every six months for three years, then yearly.
These definitions were built for reporting and comparing outcomes. The Cookson panel states that its threshold is not meant as the level at which to start treatment, and the NCI notes that a single raised value does not always mean recurrence, so clinicians look for a rising trend and may add imaging. The EAU guideline adds that, after prostatectomy, a PSA above 0.4 ng/mL best predicts later metastases, and it stops follow-up once life expectancy falls below 10 years. Ask AskMed how the AUA definition after prostatectomy differs from the Phoenix definition after radiotherapy, and which PSA level the EAU links to later metastases, and the answer quotes each source with a link.
Check a biochemical recurrence definition in AskMed:
Frequently asked questions
What PSA level is considered normal?
No level is fully normal. The NCI says no single threshold separates normal from abnormal, and more than 4.0 ng/mL is the traditional cut-off. The EAU notes that 3.0 ng/mL is the threshold screening most often uses, and age-specific thresholds run from 2.5 ng/mL in men in their 40s to 6.5 ng/mL in their 70s.
Does a high PSA mean cancer?
Not necessarily. BPH, prostatitis, infection, a recent biopsy, ejaculation and vigorous exercise can all raise PSA. The NCI notes that only about 25% of men biopsied for a raised PSA are found to have cancer, which is why the test is repeated and MRI is often done before a biopsy.
Can you have prostate cancer with a normal PSA?
Yes. In the Prostate Cancer Prevention Trial, 15.2% of men whose PSA never went above 4.0 ng/mL had cancer on biopsy, and 14.9% of those cancers had a Gleason score of 7 or higher. Even at 0.5 ng/mL or less, 6.6% had cancer.
Does finasteride affect PSA?
Yes. The EAU guideline states that 5-alpha-reductase inhibitors such as finasteride and dutasteride reduce PSA levels by 50%, so the result has to be corrected before deciding on further tests. The NCI notes that a lower abnormal cut-off is used for men taking these medicines.
How long should you avoid ejaculation before a PSA test?
The NHS advises avoiding ejaculation, anal sex, cycling and strenuous exercise for 48 hours before a PSA test, and the NCI gives the same 2-day window. After a urine infection, the NHS advises waiting 4 to 6 weeks after it clears.
How often should PSA be checked?
It depends on the guideline and the result. The AUA/SUO guideline offers screening every 2 to 4 years from 50 to 69, while the EAU repeats it every 2 years for men at risk and lets men who are not at risk wait up to 8 years. After treatment, the EAU advises PSA every six months for three years, then yearly.
Sources
- National Cancer Institute. Prostate-Specific Antigen (PSA) Test. NCI fact sheet.
- US Preventive Services Task Force. Prostate Cancer: Screening. Final Recommendation Statement. May 8, 2018.
- Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46-53.
- American Urological Association. AUA announces updates to the Early Detection of Prostate Cancer guideline. February 26, 2026 (Lin DW, Carlsson S, Filson CP, et al. J Urol. doi:10.1097/JU.0000000000004995).
- European Association of Urology. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026.
- European Association of Urology. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: Follow-up. 2026.
- Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
- Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-1777.
- Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547.
- Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650-1655.
- Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68(3):464-470.
- Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540-545.
- Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965-974.
- UK National Screening Committee. Adult screening programme: Prostate cancer. Review March 2026.
- NHS. PSA test.
- Cancer Research UK. PSA testing in patients without symptoms. Health professional pages.
- National Center for Biotechnology Information. KLK3 kallikrein related peptidase 3 (human). NCBI Gene, RefSeq summary.
